-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 14, 2022, Biohaven Pharmaceutical and Pfizer announced positive top-line results from a Phase 3 clinical trial of rimegepant in adults with acute migraine
Migraine is a very common chronic disease
This is the fourth Phase 3 clinical trial of rimegepant for the acute treatment of migraine, and the first in the Asia-Pacific region, led by BioShin, a wholly-owned subsidiary of Biohaven in the Asia-Pacific region
References:
[1] Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea.
(Original abridged)